Drug intelligence / Profile preview

JEL1103

Development stage: Unknown
Lead developer: Carocell Bio
Modality: Peptides
Administration: Topical

Overview

JEL1103 is a synthetic peptide drug candidate developed by Carocell Bio. It is being investigated as a topical anti-inflammatory treatment, with particular focus on rare skin disorders such as epidermolysis bullosa (EB), which are characterized by fragile skin and chronic inflammation. The drug is designed to be easily applied and aims to offer a safer alternative to topical steroids, which have limitations due to their safety profile. As of March 2025, JEL1103 remains in the discovery phase of development for inflammatory conditions.

Targets

RK (Ribokinase)MEK

Beyond the preview

Go deeper on JEL1103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JEL1103.

Explore the full profile